- Jagsonpal Pharmaceuticals is a specialty pharmaceutical company that sells branded prescription medicines almost entirely in India - it does not manufacture anything itself. What began in 1964 has, over decades, become a business trusted by more than 50,000 doctors, built on an asset-light model where the company invents the drug concepts in-house but outsources all production to contract manufacturers. The recurring approach is to pick a mid-sized, sub-chronic therapy area - gynaecology, orthopaedics, dermatology, paediatrics - and aim for a top-five ranking in that narrow segment, avoiding the crowded chronic-disease market where doctor incentives are common.
Business segments
A single engine - a portfolio of 75-plus branded prescription products sold through a dedicated field force to doctors across four therapy areas, with all manufacturing outsourced.
1. Branded formulations: a house of niche prescription brands
The company owns over 75 branded drugs, nine of its top ten ranked in the top five of their categories, and sells them entirely on prescription through a 1,000-strong sales force - it is a marketing and distribution engine, not a factory.
- Hormonal products are the moat - more than half of sales come from hormonal drugs, which require deep doctor engagement and trust to prescribe, so once a doctor adopts the brand, switching is rare.
- Mostly free to raise prices - 92% of the portfolio sits outside the National List of Essential Medicines, meaning the company can increase prices by up to 9.9% a year on those products without government approval.
- Gynaecology is the anchor - the company reaches roughly 90% of India's gynaecologists (35,000 out of 39,000) and ranks seventh in the therapy area, with leadership in the progesterone segment and a Dydrogesterone brand, Divatrone, that became its largest product within 18 months of launch.
- Orthopaedics is the second pillar - it reaches about 80% of orthopaedists and holds the number-two rank in the therapy area, led by Indocap, the flagship brand that was the first to cross ₹500 million in revenue.
- Dermatology and paediatrics were bought, not built - the 2024 acquisition of Yash Pharma added 33 brands, a field force of roughly 225 people, and access to dermatology and childcare markets worth approximately ₹200 billion, lifting the company's IQVIA rank by 18 places.
Sales force and distribution
A field force of about 1,000 medical representatives generates prescriptions from over 50,000 doctors, and 1,200-plus distributors push the products to more than 125,000 pharmacies across 4,000-plus towns.
- Doctors are the only customer that matters - all sales happen through prescriptions, so the company measures its business by MR productivity, doctor coverage, and call quality, not consumer advertising.
- Three therapy-specific divisions - the sales force was restructured into Boneva (orthopaedics), Fembon (gynaecology), and Naari (gynaecology) so each unit focuses on a single doctor speciality and its prescribing habits.
- A lean supply chain with no factories - 18 stocking points feed a network of 1,200-plus distributors, and the company switched from its own depots to a carrying-and-forwarding-agent model to cut costs and get closer to customers.
- The hospital channel is the newest front - in mid-2026 the company bought a 69.77% stake in Aequitas Healthcare, a Mumbai-based hospital-supply distributor, marking its first entry into institutional sales.
Group structure and partners
The company is standalone, debt-free, and jointly controlled by a Mauritius-based investment group and the founding family, with no subsidiaries until the Aequitas acquisition closed in July 2026.
- Two promoters, one board - Infinity Holdings holds 43.73% and the Kochhar family retains 24.99%, with a shareholders' agreement giving Infinity the right to nominate the Managing Director.
- Acquisitions are the growth lever - the Yash Pharma deal (2024) added dermatology and paediatrics, and the Aequitas deal (2026) opened the hospital channel, both paid in cash from internal accruals without taking on debt.
- No manufacturing subsidiaries - the company sold its only plant, in Faridabad, for ₹410 million (₹41 crores); it was already non-operational and contributed no revenue.